Micro-channel |
|
|
|
|
|
|
|
The price of "active" price reduction of enterprises is nearly 80% |
|
Author:中国铭铉 企划部 Release Time:2017-9-7 10:47:51 Number Browse:857 |
|
Medical network - on September 7, recently, the national drug supply security integrated management information platform released "about the publication of the enterprises to apply for the price of yunnan province", jiangsu side of kang pharmaceutical co., LTD. Production of the specifications of the 5 ml (including gingko diterpene lactone 25 mg) ginkgo diterpene lactone meglumine injection, nanjing pharmaceutical factory production of injection with pemetrexed disodium price respectively.
According to the securities daily, drug manufacturers including bayer and roche have cut their prices by 78.3% this year.
"This year, the medical environment has changed significantly." Third-party medical service platform MaiSiKang lai founder Shi Lichen said in an interview with "securities journal" reporter, ongoing health control, reduce the medicine proportion and to crack down on commercial bribery, make enterprise have to adjust to the idea again. "Price reduction is a trend".
Drug companies offered to lower prices
According to the information released by the government procurement and transfer center in yunnan province, the price of the aforementioned ginkgo diterpenoids, which is produced by kangyuan pharmaceutical company, will be reduced from 612.85 yuan to 316 yuan per branch, or about 48 percent. The price of the injection from nanjing pharmaceutical factory was 44.7 percent from 3,800 yuan per bottle to 2100 yuan per bottle. Among them, ginkgo diterpene ester glucosamine injection is one of the 36 negotiations that successfully entered the national health care catalog this year.
On August 31, the management of the management of Shanghai pharmaceutical centralized bidding and procurement services issued a reduction of 62 per cent to 138 yuan per box from 364.35 yuan per box.
In addition, the liaoning province procurement platform issue a notice to the five kinds of drug price reduction, including jinzhou Mr Hong pharmaceutical co., LTD. The two kinds of medicines, bayer healthcare three drugs. In zhejiang province, information on adjusting the growth statins of injection, the injection of omeprazole sodium, olaxitan injection, and canditsartan tablets were published. Anhui province has issued a notice to Shanghai roche pharmaceutical co., LTD., to apply for the company's self-produced "polyethylene glycol interferon a-2a injection" to reduce prices in the province.
It is worth mentioning that yunnan published a notice on the price adjustment of danshen injection. The price of danshen injection produced by shenwei pharmaceutical company was reduced from 9.95 yuan per branch to 2.15 yuan per branch, a decline of 78.3 percent.
In addition to medicine, there are also enterprises in the field of medical devices. For example, medtronic (Shanghai) management co., LTD. 's implantable electrocardiogram (ecg) detector, priced from $475, 000 to $38,990.
In contrast to the aforementioned drugs, some of the drugs produced by multinational companies are not falling much.
According to the information released in yunnan province, the price of imatinib, which is produced by novartis, fell from 11890 yuan/box to 10,800 yuan/box, a decline of just 9%. The price of nilotini capsules (0.2g) fell from 36600 yuan/box to 35036.04 yuan/box, a reduction of about 4%. The price of nilotini capsules (0.15 g) decreased from 29,365.42 yuan/box to 29,000 yuan/box, a reduction of about 1.2%.
According to the information from the state administration of food and drug administration, nlotini capsules are imported drugs, and novartis is the only manufacturer of the drug in China. In addition to novartis, the production enterprise of imatinib methyl sulfonate also has the pharmaceutical group oyi pharmaceutical co., LTD., jiangsu housen pharmaceutical co., LTD.
According to the research report issued by tianfeng securities, the results of the bidding results have been completed. The price pressure of generic and competitive varieties is high; The decrease of partial adjuvant medication was larger; The value of imported varieties is limited, and the price difference between the original and domestic first imitates has not been reduced.
The price reduction has become a trend
"The trend towards lower prices for health care costs is clear, and the whole pharmaceutical industry will remain under pressure for a certain period of time." The sky wind securities thinks.
"The government requires medical institutions to reduce the proportion of drugs. If companies want to go to hospitals, they have to cut prices." Mr. Shi told reporters that, especially now, the government is cracking down on commercial bribery and companies have to take steps to keep the market in place.
In addition, fierce market competition, patent expiration and so on are also one of the factors to reduce the price of drugs. For example, information released by the state administration of food and drug administration showed that up to 28 drug batches were approved for the injection of sodium permetrate.
In the industry, the price reduction is a trend. In 2016, there were only three categories of national health care catalog negotiations. In 2017, 36 products enter the national health insurance directory, most of which are multinational pharmaceutical products.
Drug companies borrowed prices in exchange for sales. Kang pharmaceutical said, ginkgo diterpene lactone meglumine injection price has certain influence to the variety profit margins, but will greatly reduce the medical expenses burden of patients, the size of the drug sales promotion play a positive role.
It is worth mentioning that the price reduction has been extended from medical insurance to non-medical products, namely self-funded drugs. According to the reporter, in order to control the proportion of drugs, some areas have already "opened the knife" to self-charge drugs.
On May 26, 2017, the Shanghai health development planning commission website issued "on further strengthening the enhancement construction and renovation of drug kickbacks implementation opinion" made it clear that the "drug administration to strengthen at its own cost, reasonable control out-of-pocket medical expenses". "Gradually reduce the cost of self-funded drugs and include the proportion of self-funded drugs in hospital performance assessment"; The self-funded drugs used by medical institutions must be purchased at a negotiated price and shall not be higher than the purchase price of the same enterprises in Beijing, tianjin and other places. In addition, the chongqing pharmaceutical exchange has also published a notice on the joint bargaining for non-medical drugs in public hospitals in chongqing municipality.
|
|
Previous article:Is it true that good death is worse than living? Talk about the overhealth of the elderly Next article:The latest speech by director of the CFDA, bi jingquan, has completely affected the pharmaceutical industry
|
|
|
|